M

MTF Biologics

Nonprofit coordinating tissue and organ donation

Manager – Regulatory Affairs

Full-TimeDeadline 6/10/27
$125k/yr
Senior
Bachelor's
Edison, NJ, USA
HybridTravel up to 20% to MTF locations and suppliers is required.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a scientific or related field, or a combination of education and equivalent work experience.
  • Seven or more years of overall experience.
  • Five years of managerial experience.
  • Five years of human tissue or medical device manufacturing experience.
  • Thorough understanding of FDA, QSR, cGMP, and ISO regulations for medical devices, diagnostics, or pharmaceuticals.
  • People-management skills and effective communication skills.
  • Attention to detail, critical thinking, problem-solving, and organizational skills.
  • Prior experience handling FDA inspections for medical devices, diagnostics, biologics, and/or pharmaceuticals.
  • Demonstrated success in obtaining U.S. FDA regulatory clearance or approval for medical technologies.
  • Ability to travel up to 20% of the time to MTF locations and suppliers as required.
Responsibilities
  • Lead, coach, and develop Regulatory Affairs staff, including staffing plans, performance management, training, and competency maintenance; actively manage and observe staff for regulatory compliance and process efficiency.
  • Assist in managing the Regulatory Affairs department budget, including salaries, benefits, external vendors and consultants, supplies, services, and internal expenses; formulate and submit budgets, manage expenses within budget requirements, and track monthly budget-to-actual performance.
  • Oversee and assist with preparing, submitting, and maintaining U.S. and international regulatory filings, including FDA, CE Marking, Canada, Australia, and other global markets.
  • Ensure maintenance of applicable licenses, AATB accreditations, and ISO 9001 and ISO 13485 certifications.
  • Participate in developing regulatory strategies and pathways to support regulatory designation of new products and tissues.
  • Serve as a primary regulatory contact during inspections and audits and lead regulatory intelligence activities.
  • Communicate and coordinate with the Vice President, MTF senior management, and other department heads on regulatory issues and strategies that may affect MTF's ability to fulfill its mission.
  • Communicate with federal and state regulatory agencies, international government bodies and notified bodies, and AATB regarding applicable new or revised regulations and standards.
  • Assist with special projects and perform additional duties as assigned.

About the company

MTF Biologics is a global nonprofit that coordinates tissue and organ donation, transplantation, and related research through a network of organ procurement and tissue recovery organizations and academic medical centers. It connects donor families with medical teams, recovers and processes donated tissues and organs, and supports implantation and transplantation across its partner institutions while funding studies to improve outcomes. Unlike for-profit competitors, it operates as a mission-driven consortium that prioritizes saving lives over commercial sales. Its goal is to increase safe tissue and organ donation, improve transplant results, and advance research in transplantation and tissue science.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Edison, New Jersey

Founded

1987

Get referred to MTF Biologics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 4, 2026 FlexHD Meshed removes intraoperative prep and shortens reconstructive procedures.
  • May 21, 2026 New Horizon distribution expands AmnioBand into post-acute and outpatient channels.
  • December 17, 2025 CMS coverage for AmnioBand and AlloPatch supports reimbursement and adoption.

What critics are saying

  • 2026 breast-mesh filings name FlexHD, threatening costly discovery and settlement pressure.
  • Donor-supply disruptions or recovery setbacks instantly constrain product availability and operating throughput.
  • Kolosis partnerships shift commercialization leverage outward, weakening MTF control over orthobiologics adoption.

What makes MTF Biologics unique

  • Nonprofit, physician-led MTF Biologics honors donated gifts and advances tissue transplantation.
  • June 2026 FlexHD Meshed widens a deep reconstructive portfolio for complex wounds.
  • Its 1987 grant program funds translational allograft science, reinforcing clinical credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Adoption Assistance

Pet Insurance

Legal Services

Company News

Business Wire
Jun 4th, 2026
MTF Biologics launches FlexHD Meshed for reconstructive surgery

MTF Biologics, a global nonprofit organisation focused on tissue transplantation, has launched FlexHD® Meshed, an extension of its FlexHD® reconstructive surgery portfolio. The pre-meshed acellular dermis matrix is designed for soft tissue defects, addressing irregular wound geometries and accelerating coverage for graft incorporation. The product eliminates the need for intraoperative preparation, reducing operating room time whilst providing immediate coverage that conforms to irregular anatomy. FlexHD® Meshed is cut from a deeper layer of dermis and aseptically processed to ensure superior handling and clinical efficacy. Developed in collaboration with surgeons treating complex wounds and deep tissue injuries, the allograft provides a structural scaffold that supports cellular repopulation and tissue integration. The product is now available through MTF Biologics.

Yahoo Finance
Apr 29th, 2026
MTF Biologics appoints Dorrie Dils to board, names David McAllister vice chair

MTF Biologics, a global nonprofit organisation focused on tissue and organ donation and transplantation, has appointed Ladora (Dorrie) Dils to its Board of Directors and named David McAllister as Vice Chair. Dils brings over three decades of experience in organ donation, currently serving as President and Chief Executive Officer of Gift of Life Michigan since 2024. She previously spent more than 20 years at Lifeline of Ohio, rising to Chief Clinical Officer. Dils is also Immediate Past President of the Association of Organ Procurement Organizations and has served on the Organ Procurement and Transplantation Network's Board of Directors. "Her expertise will be pivotal as we consider additional ways to support clinicians in saving and healing lives", said Joe Yaccarino, MTF Biologics' President and Chief Executive Officer.

Business Wire
Mar 31st, 2026
MTF Biologics and Kolosis launch DBX Fiber to expand demineralized bone matrix portfolio

MTF Biologics and Kolosis BIO have launched DBX Fiber, a new demineralized bone matrix product designed for complex spinal and orthopaedic procedures. The fibre tissue form is processed to provide surgeons with enhanced handling and osteoinductive potential in challenging fusion environments. DBX Fiber expands the existing DBX portfolio, which already includes DBX Mix and DBX Putty. The addition strengthens Kolosis' surgical biologics portfolio, which features products such as Kore Fiber, a cortical bone allograft, and Summit Matrix, a synthetic bone graft. MTF Biologics is a global nonprofit organisation focused on tissue and organ donation, transplantation and research. Kolosis BIO specialises in commercialising surgical biologics technologies across spine and orthopaedic procedures. The partnership aims to provide surgeons with greater versatility whilst maintaining trusted biologics solutions.

Business Wire
Jan 14th, 2026
MTF Biologics and Kolosis BIO launch Summit Matrix synthetic bone graft for spinal surgeries

MTF Biologics, a global nonprofit tissue and organ donation organisation, and Kolosis BIO have launched Summit Matrix, an advanced synthetic bone graft for orthopedic and spinal surgeries. The product uses NanoLift surface technology, combining nanoscale topography with biomimetic chemistry to enhance bone regeneration. Summit Matrix integrates with existing products including Kore Fiber, Prime HD and DBX Mix. Its hydroxycarbanoapatite composition mimics natural bone mineral, enabling optimal resorption and osseointegration. The nanocrystalline surface supports cell activity to promote bone formation. The launch expands the partnership between MTF Biologics, founded by orthopedic surgeons nearly 40 years ago, and Kolosis BIO, which has established itself as a leading orthobiologics provider. Together, the organisations aim to deliver innovative solutions that enhance surgical efficiency and clinical practice.

Business Wire
Mar 27th, 2024
Dr. Mia Talmor Joins The Mtf Biologics Board Of Directors

Dr. Mia Talmor, Professor of Clinical Surgery at The Weill Cornell Medical School and attending surgeon at New York Presbyterian Hospital, has joined the MTF Biologics Board of Directors. (Photo: Business Wire)Dr. Mia Talmor, Professor of Clinical Surgery at The Weill Cornell Medical School and attending surgeon at New York Presbyterian Hospital, has joined the MTF Biologics Board of Directors. (Photo: Business Wire)EDISON, N.J.--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation, has announced the appointment of Mia Talmor, MD, to the MTF Biologics Board of Directors.“We are honored to welcome Dr. Talmor to the MTF Board,” said William W